The taxoids: paclitaxel and docetaxel

scientific article published on 01 November 1994

The taxoids: paclitaxel and docetaxel is …
instance of (P31):
scholarly articleQ13442814
review articleQ7318358

External links are
P356DOI10.1016/S0140-6736(94)90754-4
P698PubMed publication ID7967989

P2093author name stringK Gelmon
P2860cites workPlant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifoliaQ34235776
Mechanism of action of taxolQ35255662
Cytotoxic studies of paclitaxel (Taxol) in human tumour cell linesQ35977537
Isolation of Chinese hamster ovary cell mutants requiring the continuous presence of taxol for cell divisionQ36207411
Phase II study of taxol in patients with untreated advanced non-small-cell lung cancerQ40720066
Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer: The Eastern Cooperative Oncology Group ResultsQ41085746
Promotion of microtubule assembly in vitro by taxolQ41461193
Phase I trial of intraperitoneal taxol: a Gynecoloic Oncology Group studyQ67520718
Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasmsQ69372459
Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patientsQ72656539
P433issue8932
P407language of work or nameEnglishQ1860
P921main subjectdocetaxelQ420436
paclitaxelQ423762
P304page(s)1267-1272
P577publication date1994-11-01
P1433published inThe LancetQ939416
P1476titleThe taxoids: paclitaxel and docetaxel
P478volume344

Reverse relations

cites work (P2860)
Q33409451A comparative analysis on the efficacy and safety of intaxel® and taxol® in advanced metastatic breast cancer.
Q74599522A review of the pharmacology and clinical activity of new chemotherapeutic agents in lung cancer
Q92619029CREPT is a novel predictor of the response to adjuvant therapy or concurrent chemoradiotherapy in esophageal squamous cell carcinoma
Q73369103Chemotherapy
Q92029848Co-encapsulation of thymoquinone with docetaxel enhances the encapsulation efficiency into PEGylated liposomes and the chemosensitivity of MCF7 breast cancer cells to docetaxel
Q38934447Dermatological adverse events with taxane chemotherapy
Q44895301Disposition kinetics of taxanes after intraperitoneal administration in rats and influence of surfactant vehicles
Q41495532Docetaxel (taxotere, Rhone-Poulenc Rorer).
Q38938154Docetaxel modulates the delayed rectifier potassium current (IK) and ATP-sensitive potassium current (IKATP) in human breast cancer cells.
Q37683970Docetaxel-loaded chitosan microspheres as a lung targeted drug delivery system: in vitro and in vivo evaluation
Q36461825Docetaxel-loaded liposomes: preparation, pH sensitivity, pharmacokinetics, and tissue distribution
Q41060508Docetaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of metastatic breast cancer
Q34739959Effectiveness of cold cap in the prevention of docetaxel-induced alopecia
Q34366588Effects of valproic acid on the cell cycle and apoptosis through acetylation of histone and tubulin in a scirrhous gastric cancer cell line
Q44533626Enhanced effectiveness of last generation antiblastic compounds vs. cisplatin on malignant pleural mesothelioma cell lines
Q42006799Enhanced oral delivery of docetaxel using thiolated chitosan nanoparticles: preparation, in vitro and in vivo studies
Q40521965Evaluation of the effects and adverse drug reactions of low-dose dexamethasone premedication with weekly docetaxel
Q53289282Genome-Wide Association Study on Overall Survival of Advanced Non-small Cell Lung Cancer Patients Treated with Carboplatin and Paclitaxel
Q44144949Growth-inhibiting effects of intralesional docetaxel and paclitaxel on an experimental model of malignant neuroectodermal tumor
Q37559448Impact of Symptom Clusters on Quality of Life Outcomes in Patients from Japan with Advanced Nonsmall Cell Lung Cancers
Q93896531In vitro synergy of paclitaxel (Taxol) and vinorelbine (navelbine) against human melanoma cell lines
Q44711355Influence of neoadjuvant therapy with epirubicin and docetaxel on the expression of HER2/neu in patients with breast cancer.
Q39312964Inhibition of nuclear factor-κB enhances the antitumor effect of paclitaxel against gastric cancer with peritoneal dissemination in mice.
Q44969545Lack of association between amplification of her-2 and response to preoperative taxanes in patients with breast carcinoma
Q43701818Low-dose paclitaxel ameliorates renal fibrosis in rat UUO model by inhibition of TGF-beta/Smad activity
Q39188081Low-dose paclitaxel modulates tumour fibrosis in gastric cancer
Q90974929MicroRNA-421 confers paclitaxel resistance by binding to the KEAP1 3'UTR and predicts poor survival in non-small cell lung cancer
Q40947187N-(4-hydroxyphenyl) retinamide inhibits cystogenesis by polycystic epithelial cell lines in vitro
Q37473193Nanoformulation of natural products for prevention and therapy of prostate cancer
Q36137260Nanoparticulated docetaxel exerts enhanced anticancer efficacy and overcomes existing limitations of traditional drugs
Q34432179Novel molecules that interact with microtubules and have functional activity similar to Taxol
Q33978189Paclitaxel ameliorates fibrosis in hepatic stellate cells via inhibition of TGF-beta/Smad activity
Q36607944Paclitaxel interrupts TGF-beta1 signaling between gallbladder epithelial cells and myofibroblasts
Q34458673Paclitaxel: a pharmacoeconomic review of its use in non-small cell lung cancer
Q41440111Pharmacokinetic optimisation of cancer chemotherapy. Effect on outcomes
Q35010568Phase I dose-finding study of cabazitaxel administered weekly in patients with advanced solid tumours
Q55286232Phase I study of third-line palliative chemotherapy with low dose paclitaxel for pancreatic cancer.
Q33686177Phase I study of weekly palliative chemotherapy with low-dose third-line paclitaxel for biliary tract cancer
Q52207123Phase I/II trial of high dose mitoxantrone in metastatic breast cancer: the M.D. Anderson Cancer Center experience.
Q33362114Phase II trial of dose-dense paclitaxel, cisplatin, 5-fluorouracil, and leucovorin with filgrastim support in patients with squamous cell carcinoma of the head and neck
Q26748931Predictive value of BRCA1 expression on the efficacy of chemotherapy based on anti-microtubule agents: a pooled analysis across different malignancies and agents
Q44558863Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing docetaxel
Q36644465Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines.
Q43703440Rapid high-performance liquid chromatographic determination of docetaxel (Taxotere) in plasma using liquid-liquid extraction
Q35052282Recent advances in the systemic therapy of breast cancer.
Q38077764Safety and efficacy of cabazitaxel in the docetaxel-treated patients with hormone-refractory prostate cancer.
Q36424414Six minute walking test and carbon monoxide diffusing capacity for non-small cell lung cancer: easy performed tests in every day practice
Q36424359Successful treatment of unresectable gallbladder cancer with low-dose paclitaxel as palliative chemotherapy after failure of gemcitabine and oral S-1: A case report
Q33916040Targeted delivery of albumin bound paclitaxel in the treatment of advanced breast cancer
Q27023361Targeted therapy using nanotechnology: focus on cancer
Q33800977Taxanes: an overview of the pharmacokinetics and pharmacodynamics
Q34451466The role of plant-derived drugs and herbal medicines in healthcare
Q33642860Traditional pharmacology and medicine in Africa. Ethnopharmacological themes in sub-Saharan art objects and utensils
Q34299276Treatment of HIV-associated Kaposi's sarcoma with paclitaxel
Q73209055[Neurologic complications of chemotherapy]
Q79305388[Onycholysis with hyponychium exudate secondary to chemotherapy with paclitaxel and capecitabine]

Search more.